Unlocking Potential. Faster.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in adjunct cancer care, oncology, stem cell therapy and unique prescription products.
Our team’s extensive experience in the pharmaceutical industry allows us to identify compelling opportunities and develop assets that have unique commercial advantages and differentiated upside potential. By deploying capital thoughtfully, we believe our activities will provide patients and caregivers with improved treatment options and deliver long-term sustainable value to shareholders.
Our diversified pipeline of therapies targeting unmet medical needs includes three potential first-and-only prescription treatments in their indications, and a next-generation single-donor, allogeneic, clonal and scalable stem cell therapy program.
Learn more about Mino-Lok...
Learn more about Halo-Lido…
Learn more about Mino-Wrap…
Learn more about our Stem Cell Platform...